No abstract

No abstract

Background: Diabetes mellitus is a major public health problem. It is worldwide & a major risk factor for cardiovascular diseases. Glibenclamide and Glimepiride are widely used second generation sulfonylurea antidiabetic drugs. Both Glibenclamide and Glimepiride stimulate release of insulin from pancreatic acinar cells, by blocking an ATP-sensitive potassium channel. Therefore we evaluated the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin in patients of type II diabetes mellitus. Aims & Objective:(1) To find out the demographic profile of type II diabetes mellitus. (2) To find out the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) in type II diabetes mellitus Patients. (3) To compare the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) among the two study groups. Material and Methods: A prospective, randomized, open, parallel group study was carried out in patients attending OPD of Medicine department MM Institute of Medical Sciences and Research (MMIMSR), Mullana, Ambala. 50 patients were randomly assigned into groups A & group B. In Group A (n=25) Glibenclamide (5-15 mg/day) & in Group B (n=25) Glimepiride (1-6 mg/day) was administered for a period of 24 weeks. Data analyzed by Student's "t"-test.Results: It was found that prevalence of type II diabetes mellitus is more common among the male patients There was a significant reduction in glycosylated haemoglobin score (p<0.05) in both the study groups after 24 weeks but glycosylated haemoglobin level did not differ significantly (p>0.05) between the two groups. Conclusion: Glibenclamide and Glimepiride lowered glycosylated haemoglobin to a similar degree without significant difference between the two groups.

No abstract